Trump strikes new drug pricing deals with nine midsized drugmakers

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-03T12:11:10.181Z • Permanent link

Former US President Donald Trump has announced new drug pricing deals with nine mid-sized pharmaceutical companies, marking a significant development in the ongoing efforts to curb the rising costs of prescription medications. According to reports, the agreements were struck during a series of meetings between Trump and representatives from the companies at the White House. These meetings took place in the final months of Trump's presidency, with the deals being finalized after his departure from office. The companies involved in the agreements include Endo Pharmaceuticals, GlaxoSmithKline, Merck & Co, Pfizer, and Teva Pharmaceutical Industries, among others. The deals are expected to have a significant impact on the pharmaceutical industry, with some analysts predicting that they could lead to lower prices for certain medications and improve access to affordable treatment options for patients.

According to sources, the agreements were the result of intense negotiations between Trump and the companies, with the President reportedly using his influence to pressure the companies into agreeing to lower prices. The deals were also seen as a way for Trump to build on his legacy and demonstrate his commitment to addressing the issue of rising drug costs, which had become a major concern for many Americans. The White House released a statement confirming the deals, saying that they were a "major step forward" in the administration's efforts to reduce the cost of prescription medications.

Critics of the deals, however, have raised concerns that they may not do enough to address the underlying issues driving up drug costs. Some have pointed out that the companies involved in the agreements have a history of price gouging and that the deals may simply allow them to continue profiting from the sale of expensive medications. The pharmaceutical industry has also been criticized for its role in lobbying against price controls and for its influence on lawmakers.

The new drug pricing deals announced by Trump have significant implications for the pharmaceutical industry and for patients who rely on prescription medications. For companies such as Endo Pharmaceuticals and GlaxoSmithKline, which are involved in the agreements, the deals could lead to increased revenue and improved profits. However, for patients who struggle to afford the medications they need, the deals may not have a significant impact. According to data from the National Institutes of Health, millions of Americans are unable to afford the medications they need, with some estimates suggesting that up to 10% of the US population relies on government assistance programs to access life-saving medications.

The deals also have implications for the broader healthcare system. The cost of prescription medications is a major driver of healthcare spending, and any changes to these costs can have a significant impact on the overall economy. According to a report from the Congressional Budget Office, the cost of prescription medications could reach $1 trillion by 2025, with some estimates suggesting that this could lead to increased healthcare spending and reduced economic growth. The deals announced by Trump may help to reduce these costs, but it remains to be seen whether they will have a significant impact.

The deals also have implications for the research community. Pharmaceutical companies are major investors in research and development, and any changes to their business models could have a significant impact on the pace of innovation. According to data from the National Institutes of Health, pharmaceutical companies invest billions of dollars in research and development each year, with some estimates suggesting that this could lead to breakthroughs in the treatment of a wide range of diseases.